Limits...
Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.

Mindrescu C, Gupta RP, Hermance EV, DeVoe MC, Soma VR, Coppola JT, Staniloae CS - Vasc Health Risk Manag (2008)

Bottom Line: These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003).In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline.However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (-0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001).

View Article: PubMed Central - PubMed

Affiliation: Comprehensive Cardiovascular Center, Saint Vincent's Hospital Manhattan, 170 West 12th Street, New York, NY 10011, USA.

ABSTRACT

Background: The present study was undertaken to investigate the effect of statins plus omega-3 polyunsaturated fatty acids (PUFAs) on endothelial function and lipid profile in South Asians with dyslipidemia and endothelial dysfunction, a population at high risk for premature coronary artery disease.

Methods: Thirty subjects were randomized to rosuvastatin 10 mg and omega-3-PUFAs 4 g or rosuvastatin 10 mg. After 4 weeks, omega-3-PUFAs were removed from the first group and added to subjects in the second group. All subjects underwent baseline, 4-, and 8-week assessment of endothelial function and lipid profile.

Results: Compared to baseline, omega-3-PUFAs plus rosuvastatin improved endothelial-dependent vasodilation (EDV: -1.42% to 11.36%, p = 0.001), and endothelial-independent vasodilation (EIV: 3.4% to 17.37%, p = 0.002). These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003). In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline. However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (-0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001). Addition of omega-3-PUFAs further improved the lipid profile (triglycerides 139 to 91 mg/dl, p = 0.006, low-density lipoprotein cholesterol 116 to 88 mg/dl, p = 0.014).

Conclusions: Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial function in South Asian subjects with dyslipidemia and endothelial dysfunction.

Show MeSH

Related in: MedlinePlus

Study design: An open-label, randomized cross-over study. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.Abbreviations: Ro, rosuvastatin; Omega-3 PUFAs, Omega-3 polyunsaturated fatty acids.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2663433&req=5

f1-vhrm-4-1439: Study design: An open-label, randomized cross-over study. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.Abbreviations: Ro, rosuvastatin; Omega-3 PUFAs, Omega-3 polyunsaturated fatty acids.

Mentions: After the initial endothelial function assessment, patients were randomized in a crossover design between 2 drug regimens: rosuvastatin 10 mg along with omega-3 fatty acid supplements (Fish oil capsules 4.53 g DHA/EPA, N3 Oceanic Inc., Palm, PA, USA) (Group 1) or rosuvastatin 10 mg alone (Group 2) as shown in Figure 1. After 4 weeks, the omega-3 PUFAs supplements were removed from the treatment of Group 1 and added to the subjects in Group 2. Each patient served as his own control. The omega-3 fatty acid supplement capsules contained 430 mg EPA, 325 mg DHA, gelatin, glycerine, purified water, and natural lemon flavor as other ingredients. Subjects received 2 capsules three times per day. Patients taking statin medication were asked to stop that medication for four weeks before entering the study. All subjects maintained the same medication other than the study medication throughout the duration of the study. Compliance with the medication was assessed by pill count at each visit and at the end of the study.


Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia.

Mindrescu C, Gupta RP, Hermance EV, DeVoe MC, Soma VR, Coppola JT, Staniloae CS - Vasc Health Risk Manag (2008)

Study design: An open-label, randomized cross-over study. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.Abbreviations: Ro, rosuvastatin; Omega-3 PUFAs, Omega-3 polyunsaturated fatty acids.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2663433&req=5

f1-vhrm-4-1439: Study design: An open-label, randomized cross-over study. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.Abbreviations: Ro, rosuvastatin; Omega-3 PUFAs, Omega-3 polyunsaturated fatty acids.
Mentions: After the initial endothelial function assessment, patients were randomized in a crossover design between 2 drug regimens: rosuvastatin 10 mg along with omega-3 fatty acid supplements (Fish oil capsules 4.53 g DHA/EPA, N3 Oceanic Inc., Palm, PA, USA) (Group 1) or rosuvastatin 10 mg alone (Group 2) as shown in Figure 1. After 4 weeks, the omega-3 PUFAs supplements were removed from the treatment of Group 1 and added to the subjects in Group 2. Each patient served as his own control. The omega-3 fatty acid supplement capsules contained 430 mg EPA, 325 mg DHA, gelatin, glycerine, purified water, and natural lemon flavor as other ingredients. Subjects received 2 capsules three times per day. Patients taking statin medication were asked to stop that medication for four weeks before entering the study. All subjects maintained the same medication other than the study medication throughout the duration of the study. Compliance with the medication was assessed by pill count at each visit and at the end of the study.

Bottom Line: These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003).In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline.However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (-0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001).

View Article: PubMed Central - PubMed

Affiliation: Comprehensive Cardiovascular Center, Saint Vincent's Hospital Manhattan, 170 West 12th Street, New York, NY 10011, USA.

ABSTRACT

Background: The present study was undertaken to investigate the effect of statins plus omega-3 polyunsaturated fatty acids (PUFAs) on endothelial function and lipid profile in South Asians with dyslipidemia and endothelial dysfunction, a population at high risk for premature coronary artery disease.

Methods: Thirty subjects were randomized to rosuvastatin 10 mg and omega-3-PUFAs 4 g or rosuvastatin 10 mg. After 4 weeks, omega-3-PUFAs were removed from the first group and added to subjects in the second group. All subjects underwent baseline, 4-, and 8-week assessment of endothelial function and lipid profile.

Results: Compared to baseline, omega-3-PUFAs plus rosuvastatin improved endothelial-dependent vasodilation (EDV: -1.42% to 11.36%, p = 0.001), and endothelial-independent vasodilation (EIV: 3.4% to 17.37%, p = 0.002). These effects were lost when omega-3-PUFAs were removed (EDV: 11.36% to 0.59%, p = 0.003). In the second group, rosuvastatin alone failed to improve both EDV and EIV compared to baseline. However, adding omega-3-PUFAs to rosuvastatin, significantly improved EDV (-0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001). Addition of omega-3-PUFAs further improved the lipid profile (triglycerides 139 to 91 mg/dl, p = 0.006, low-density lipoprotein cholesterol 116 to 88 mg/dl, p = 0.014).

Conclusions: Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial function in South Asian subjects with dyslipidemia and endothelial dysfunction.

Show MeSH
Related in: MedlinePlus